Fifteen bovine herpesvirus-1 (BHV-1)-negative calves were vaccinated intramuscularly with 10 7.4 plaque-forming units of a double-deletion BHV-1 mutant (IBRV(NG)dltkdlgIII), and 6 remained as nonvaccinated controls. Thirty days after vaccination, the animals were challenged by nasal instillation of 10 8.2 CCID 50 of a virulent BHV-1 strain (Cooper). The vaccinated calves were protected against wildtype virus challenge as demonstrated by clinical evaluation. Most of the vaccinates developed only a mild rhinitis (lasting an average of 6.5 days) with almost no systemic symptoms, whereas the controls developed a serious illness characterized by rhinitis (X = 11.5 days), conjunctivitis, hyperthermia, apathy, loss of appetite, and dyspnea. The vaccinates also shed significantly less virus and for a shorter period of time (X = 5.5 days) than the controls (X = 9 days). Thirty days after vaccination, the vaccinates were negative in an anti-gIII specific blocking enzyme-linked immunosorbent assay (ELISA), despite the fact that most of them had developed neutralizing antibodies (serum neutralization titers ranging from 1:2 to 1: 16). Seroconversion to gIII was detected as early as 7 days postinfection (dpi). Fourteen days after the challenge, all the animals exposed to wildtype BHV-1 had developed anti-gIII antibodies and were positive in this differential serologic test. Six controls plus 8 vaccinates kept in isolation were still positive to gIII when tested at 75 dpi. The use of the IBRV(NG)dltkdlgIII strain in conjunction with an anti-gIII specific blocking ELISA kit represents a powerful tool for BHV-1 control/eradication programs. nella), the Division of Biochemical Virology, Baylor College of Medicine, Houston, TX 77030 (S. Kit), and Novagene, Inc., Houston, diagnosis between vaccine-induced and wildtype vi-TX 77027 (M. Kit).
Bovine herpesvirus type 1 (BHV-1), also known as However, these traditional vaccines induce an aninfectious bovine rhinotracheitis virus (IBRV), is the tibody response that is indistinguishable from that proetiologic agent of important diseases of cattle, such as duced in response to natural infection. Thus, all seinfectious bovine rhinotracheitis (IBR), vulvovaginitis ropositive animals tend to be considered potential (IPV), balanopostitis (IBP), abortion, encephalitis in carriers of the virus, complicating the establishment calves, and fatal multisystemic infection in new-of control measures regarding cattle movement, trade, borns 5,15 Bovine herpesvirus-1, like other alphaher-. import/export, and certification of BHV-1 -free herds. pesviruses, can establish latency in neural sensory ganglia and can be reactivated either by stressful conditions A few years ago, a new temperature-resistant, genetically engineered BHV-1 strain was described as a or by corticosteroid treatment. 1, 19 potential vaccine candidate. 8 This strain, denominated Bovine herpesvirus-1 infection constitutes one of the IBRV(NG)dltk, was derived from the parental BHV-1 most important infectious diseases of cattle and causes significant economic losses to livestock around the "Los Angeles" strain and contained a 343-bp deletion in the thymidine kinase (tk) gene as the principal basis world. Because of its sanitary and economic impact, for its attenuation. Thymidine kinase-negative (tk-) several countries are concentrating efforts to control or BHV-1 mutants are highly attenuated and stable when eradicate BHV-1 infection. Inactivated and modified inoculated in calves and safe for use in pregnant cows. 8, 11 live vaccines (MLV) have been used with relative suc-Recently, the same authors engineered a second gencess for many years to prevent the losses from BHV-1 eration vaccine, with deletions in both tk and gIII gene, infection.
named IBRV(NG)dltkdlgIII. 7 The gIII gene encodes a 92,000-95,000-dalton glycoprotein (gp92), which is one From the Department of Veterinary and Biomedical Sciences, of the major BHV-1 envelope glycoproteins. 6, 12, 16, 17 The University of Nebraska, Lincoln, NE 68583 (Flores, Osorio, Za-deletion of the gIII gene would permit a differential nated animals from BHV-1 latently infected carriers. This principle is proving successful in the control/eradication of pseudorabies in several countries. 6, 23 The objective of this experiment was to test the ability of the double deletion mutant IBRV(NG)dltkdlgIII strain to prevent clinical respiratory disease following exposure to a virulent BHV-1 strain while permitting a differential diagnosis by the use of an anti-gIII specific blocking enzyme-linked immunosorbent assay (ELISA).
Materials and methods
Experimental design. Twenty-one 8-10-mo-old calves from a BHV-1-free herd (minimal disease incidence herd, University of Nebraska, Mead, NE) were used in this experiment. The animals were divided in 2 groups: 15 to be vaccinated and 6 to remain as nonvaccinated controls and housed in isolation rooms at 2 animals/room. After a 7-day adaptation period, the animals were vaccinated intramuscularly with the double deletion mutant strain of BHV-1. Thirty days later, both groups (vaccinates and controls) were challenged by nasal instillation of a highly virulent BHV-1 strain (Cooper). After the challenge, the animals were clinically monitored up to 20 days postinfection (dpi). Blood for serology was collected at the day of vaccination, at the day of challenge, daily up to 15 dpi, and then at 21 and 28 dpi. Blood samples from the controls and 8 of the vaccinates were also collected at 75 dpi. Nasal swabs for virus isolation were collected at days 0, 3, 6, and 9 after vaccination; immediately prior to challenge, and daily from 2 to 16 dpi.
Vaccine.
A temperature-resistant deletion mutant strain of BHV-1 (IBRV(NG)dltkdlgIII), which is derived from the parental BHV-1 (IBRV "Los Angeles"), was used as a vaccine. This strain was first attenuated by passage in rabbit skin cells in a medium containing 1-ß-D arabinofuranosylthymine and 5-bromodeoxiuridine, followed by a deletion of 343 bp in the thymidine kinase gene into which place was inserted a 40-nucleotide proprietary sequence containing stop signals in the 3 reading frames. The differential characteristic of this strain was achieved by engineering a 1,535-bp "marker" deletion in the gIII gene. 9 The animals were vaccinated intramuscularly by inoculation of 10 7.4 plaque-forming units of IBRV(NG)dltkdlgIII contained in 2 ml of minimal essential medium (MEM) plus 5% horse serum a (HS). The controls received only placebo (MEM + 5% HS).
Challenge virus. The highly virulent BHV-1 (IBRV Cooper strain) was provided by the USDA b and used to challenge the calves with a dose of 10 8.2 CCID 50 diluted in 4 ml of MEM. Each animal was challenged by aerosol instillation of 2 ml of the viral suspension in each nasal cavity.
Clinical evaluation. To obtain an individual baseline of the clinical parameters, the animals were examined daily, starting 7 days before the challenge. After the challenge, the animals were clinically monitored on a daily basis from 2 dpi to 20 dpi. The following clinical parameters were assessed: temperature, respiratory rate, alertness, appetite, rhi- nitis, nasal discharge, conjunctivitis, ocular discharge, dyspnea, coughing and respiratory rales. Each parameter received a score ranging from 0 (-) to 4 (+ + + +), depending on the degree of clinical severity (Table 1) .
Serum neutralization (SN) assays. Serum samples were obtained on the day of vaccination, on the day of challenge, and 7, 14, 21, and 28 dpi (and from the controls plus 8 of the vaccinates at 75 dpi) for SN assays as previously described. 4 The assays were performed in microtiter plates" using 2-fold dilutions of heat-inactivated serum sample (56 C for 30 min) incubated with approximately 100 CCID 50 of BHV-1 (IBRV Cooper) and bovine turbinate d (BT) cells as an indicator system. All samples were run in triplicate, and the final readings were performed after 7 days of incubation at 37 C in a 5% CO 2 atmosphere. 3, 6, and 9 after vaccination and at the day of challenge were inoculated onto BT cells to assess possible shedding of the vaccine virus and were considered negative for BHV-1 after 3 passages with no noticeable cytopathic effect (CPE). The material from the nasal swabs collected 2-15 dpi was used for virus titration. Ten-fold dilutions of swab medium were incubated with a suspension of BT cells. The virus titers were calculated according to the Reed and Muench method. For those samples in which no infectious virus was detected at the 10 -1 dilution, raw material from swabs was directly inoculated onto BT cells. No swab collection was made at the first day after challenge to avoid possible detection of residual challenge virus. For both virus isolation and titration, the plates were monitored daily for characteristic BHV-1 CPE, and the final readings were taken after 7 days of incubation.
Viral isolation and titration. Nasal swabs obtained at days
Specific anti-gIII blocking ELISA. Serum samples were obtained from all the animals 30 days after vaccination (immediately prior challenge), and 7, 9, 11, 14, 21, and 28 dpi and from 8 vaccinates and the controls at 75 dpi for a specific blocking ELISA to detect antibodies against the BHV-1 glycoprotein gIII (gp92). 10 This differential test is performed on microtiter test plates coated with partially purified BHV-1 (IBRV "Los Angeles") virus antigen. One hundred microliters of test and positive and negative control serum are added to each well and incubated for 2 hr at room temperature. The serum is removed, and the wells are washed 3 times with TEN buffer. The monoclonal anti-gIII antibody conjugated with horseradish peroxidase (HRPO) is used at a dilution 1:600 in 10% equine serum phosphate-buffered saline (PBS). One hundred microliters are added per well and incubated 30 min at room temperature. The fluid is then removed, and the wells are washed 5 times with TEN buffer. Then, 100 µ1 of a mixture (1: 1) of TMB microwell peroxidase substrate e and peroxidase substrate solution B e are added per well and incubated at the room temperature for 20 min. Fifty microliters of a stop solution (0.01% sodium azide) are then added per well, and after gently shaking, the plates are read in an ELISA reader f at 650 nm. The optical density (OD) of each sample is reported and divided by the OD of the negative control sample giving the S/N ratio. Samples with an S/N ratio >0.75 are considered negative; samples with an Figure 2 . Clinical score in calves following intranasal challenge with a virulent bovine herpesvirus-l (IBRV Cooper strain). Each value represents the average of the cumulative individual score for control or vaccinated groups. The scores were quantitated according to the scale (0-4) described in Table 1. S/N ratio <0.65 are considered positive, and samples with an S/N ratio between 0.65 and 0.75 are considered suspicious.
Specific anti-IgM capture ELISA. Serum samples were obtained at the day of vaccination, at the day of challenge, and at 3, 5, 6, 7, 9, 11, 14, 21, and 28 dpi for an anti-IgM specific capture ELISA as previously described. 18 This test is done on sera diluted 1:20 in PBS-Tween 20 g + 4% turkey serum, murine-specific anti-bovine IgM monoclonal antibody (DAS-11 h ) adsorbed to a solid phase, murine monoclonal antibodies (MAbs) against BHV-1 (MAbs 113 and 155) conjugated to HRPO, h and ABTS peroxidase substrate. e The plates are read in an ELISA reader f at 405 nm. The OD of each sample is reported, and the S/N ratio is calculated. Samples with a S/N ratio > 2.0 are considered positive, and samples with a S/N ratio < 2.0 are considered negative.
Results
Clinical response to challenge. The clinical response of the vaccinated and control calves to challenge with virulent IBRV is summarized in Figs. 1 and 2 and in Table 1 . In general, the controls were significantly more affected for a longer period of time than were the vaccinates, as demonstrated by the average clinical score (Fig. 2 ). All the controls had an increased body temperature, which lasted an average of 5 days (range 3-6 days). Nine of the vaccinates (60%) also had hyperthermia, which lasted an average of 1.5 days (range 1-3 days) ( Fig. 1) .
All of the controls showed reduction in alertness and appetite, ranging from moderate to marked. Apathy was noticeable for 8-15 days (X = 10 days), and the loss of appetite usually lasted for 2-3 days only. One control animal had severe apathy that lasted for 15 days. Apathy was noticed in 3 (20%) of the vaccinates. Two of them developed very mild apathy (1-3 days), and 1 had moderate apathy (6 days) and loss of appetite (2 days). The rest of the vaccinates showed no noticeable change either in alertness or appetite.
All the controls developed different degrees of rhinitis (marked to severe degrees, with necrofibrinotic lesions and catarrhal to mucopurulent discharge). The rhinitis lasted from 7 to 16 days (X = 11.5 days), and the nasal discharge usually remained for 3-6 days after other clinical signs had disappeared. The vaccinates developed significantly less severe nasal signs. Five (33%) showed only mild redness and slight serous discharge, 9 (60%) developed moderate redness and serocatarrhal discharge, and only 1 had severe rhinitis and nasal discharge, (which was less severe than that developed by the controls). In the vaccinates, the rhinitis symptoms lasted an average of 6.5 days (range, 4-10 days).
All the controls developed mild to moderate degrees of conjunctivitis associated with slight serous to seromucous ocular discharge (lasting 4-7 days), whereas noticeable conjunctivitis (very mild) was reported in only 2 vaccinated calves. Two of the vaccinates showed slight serous ocular discharge without any other sign of conjunctivitis.
The controls developed different degrees of dyspnea, ranging from moderate to marked, that lasted an average of 8 days (range 5-11 days). Five of 15 (33%) vaccinates also developed dyspnea: 4 vaccinates had mild to moderate dyspnea characterized only by increased respiratory rate, whereas 1 had marked respiratory distress, comparable to that developed by the controls, that lasted 5 days. Two controls showed abnormal bronchopulmonary sounds that lasted 2-3 days. No coughing was noticeable among the animals during the experiment.
Virus shedding. No infectious virus was detected in
the nasal swabs collected from the vaccinated animals at 3, 6, and 9 days postvaccination and immediately prior to challenge. After challenge, the vaccinated animals shed significantly less virus and for less time than did the controls (Fig. 3) . The average titer of virus shed by the vaccinates was lower than that of the controls from 2 dpi through 7 dpi and the period of virus excretion was 5.5 days (range, 4-7 days) for the vaccinates and 9 days (range, 7-11 days) for the controls. No virus was detected in the nasal swabs of the vaccinates after 7 dpi, whereas the controls kept shedding virus until 12 dpi.
Serum neutralization assays. Thirty days after vaccination, 12 (80%) of the vaccinates had developed neutralizing antibodies against BHV-1 (from 1:2 to 1:16), whereas 3 (20%) of the vaccinates and the 6 controls showed no detectable seroconversion (data not shown). After challenge, all the vaccinates showed a significant increase in serum neutralizing antibodies, as demonstrated by SN assays performed with serum collected at 7 dpi (titer range: 1:64-1:256). These titers generally remained at these levels until 28 dpi (Fig.  4a ). The controls had detectable SN titers only in the samples collected at 14 dpi and maintained these levels until 28 dpi. At 75 dpi, the SN titers of the controls and of 8 of the vaccinates had decreased but were still positive (titer range: 1: 16-l : 128).
Specific anti-gIII blocking ELISA. At the day of the challenge (30 days after vaccination), all of the animals (controls and vaccinates) were negative (i.e., S/N ≥ 0.75) in the anti-gIII ELISA (data not shown). The serum sample of 1 of the vaccinates had a S/N ratio of 0.73 (negative, but within the suspect range). This sample was tested 2 more times, with the same result (S/N ratios of 0.73 and 0.74, respectively). The seroconversion to gIII was detected as early as 7 dpi in some vaccinates and 9-11 dpi for most of the controls (Fig. 4b) . At 14 dpi, all animals had seroconverted to gIII, and they maintained this status when tested again at 28 dpi. Serum samples collected from the 6 controls plus 8 vaccinates at 75 dpi were still positive for gIII (Table 2, Fig. 4b ).
Anti-IgM specific capture assay. The IgM response of calves after vaccination and challenge is shown in Figure 4c . Thirty days after vaccination, the serum samples of most of the vaccinates showed no anti-IBRV detectable IgM response. The IgM response they developed after the vaccination probably had decreased to levels that could not be detected with this test. In the controls, the IgM response postchallenge was first detected at 8 dpi, reached a peak at 14 dpi, and then declined progressively until 28 dpi. On that day, 4 of the controls (66%) remained positive, but the average of the group had dropped below the cutoff value. Most of the vaccinates showed only a slight increase in IgM levels after challenge, without reaching the cutoff value (Fig. 4c) . Three of the vaccinates showed a considerable IgM response, reaching levels above the Table 2 . Antibody response* to gIII glycoprotein in calves vaccinated with a double deletion mutant bovine herpesvirus-l (IBRV(NG)dltkdlgIII) and challenged with virulent BHV-1 (IBRV Cooper strain). able tools to be used as vaccines. 6, 8, 10, 23 Pseudorabies virus (PRV) tk-mutant vaccines, some of them containing "marker" deletions, are being successfully used to control Aujeszky's disease in the USA, Japan, New Zealand, and some European countries. 9,23 Bovine herpesvirus-1 (BHWIBRV) tk-mutants are also genetically stable, safe, and effective in protecting animals against wildtype virus infections and constitute promising vaccine candidates. 8, 11 In a search for a "marker" BHV-1 vaccine, a second deletion was engineered in the parental tk-BHV-1 (IBRVdltk), deleting 1,535 bp of the gIII gene. 9 The ability of the parental IBRVdltk strain to replicate well at 40 C represents an advantage over some of the other BHV-1 vaccines, because it can be administered intramuscularly. 6, 7 In the present experiment, the clinical protection achieved by intramuscular vaccination with IBRV(NG)dltkdlgIII clearly showed that the second cutoff value but still remaining below the levels reached (gIII) deletion had no major adverse effects on the biby the controls.
ology and immunogenicity of the strain. Although ex-
Discussion
posure to the high doses of virus used to challenge the animals in this experiment is highly unlikely to occur Previous studies have shown that tk-herpesvirus under natural conditions, the vaccinates were satisfacmutants are highly attenuated, thus representing valu-torily protected as compared with the controls. The degree and duration of the disease were significantly reduced in the vaccinates; most of them developed only a transient and mild rhinitis without any other adverse effect in alertness, appetite, or body condition.
The choice of gIII as a serologic marker was based on some of its characteristics: gIII(gp92-95,000) is one of the major envelope glycoproteins, 6, 12, 16, 22 is immunogenic, 6,14 and is ubiquitous among BHV-1 field strains. The gIII-negative phenotype of the IBRV(NG)dltkdlgIII was confirmed by studies showing that extract of cells infected with this strain did not contain immunologically active gIII protein in contrast with extract of cells infected with field strains. 6, 7 tines is their inability to completely inhibit the replication and shedding of the field strains in a subsequent exposure. Some inactivated vaccines are able to reduce the BHV-1 wildtype virus replication and shedding only slightly.
2 0 The results of this study indicate that vaccination with IBRV(NG)dltkdlgIII significantly reduced both the extent and duration of the challenge virus shedding, as has been previously shown for some BHV-1 modified live vaccines. 2 The epidemiologic significance of this fact is that vaccination would also help in reducing the spread of the virus and consequently the number of infected animals in the herd and in the surrounding areas. The gIII product plays an important role in the BHV-1 infection, and its deletion could somehow affect the biology of the virus. The gIII is the most abundant glycoprotein expressed by 12, 16, 17 and it is an efficient target for neutralizing antibodies and cytotoxic T cells. 21 Numerous lines of evidence support the idea that gIII functions as the predominant viral attachment protein1 2,14,17 and participates in virus penetration into the host cells. 12 As recently demonstrated by single-step growth experiments, gIII-negative mutants yield lower titers of BHV-1 than of wildtype virus, suggesting that this protein may also play a role in other events in virus replication. 4 Despite these important functions attributed to gIII, recent studies have demonstrated that it is nonessential for virus growth in tissue culture. 23 Although they retain the ability to establish infections in cattle after intranasal exposure, the gIII-negative mutants replicate much less efficiently than the wildtype virus does within the host tissues. 12 These findings support the idea that gIII may be important for virus survival in its natural environment. 12 Although it is the major envelope glycoprotein, gIII may not play an essential role in the induction of a protective immune response. A previous study showed no significant difference between the immunogenicity, as measured by antibody production and protection, of a gIII-negative mutant and a wildtype virus strain. 12 Because BHV-1 expresses several other surface glycoproteins (gI, II, and IV 16 ), the removal of a single antigen may not adversely affect the immunogenicity of the virus.
The results of the specific anti-gIII ELISA showed that the antibody response to the gIII-negative strain can be readily differentiated from that induced by the wildtype virus, as shown previously. 10 The vaccinates did not develop any measurable antibody response to gIII at 30 days after vaccination, despite the fact that most of them had developed SN antibodies. After challenge with a wildtype gIII+ virus, they developed anti-gIII antibodies, which remained at detectable levels during the entire experiment, as demonstrated by samples from the controls and 8 of the vaccinates tested at 75 dpi. Further studies using different field strains and doses and sampling for a longer period postinfection are required to determine how long these anti-gIII antibodies persist at detectable levels. The detection of anti-BHV-1 antibodies for a long time after infection is of pivotal importance because it allows the detection of latently infected animals. 10 The specificity of the anti-gIII ELISA has been previously demonstrated by showing that bovine antisera to coronavirus, respiratory syncytial virus, rotavirus, Parainfluenza-3, bovine viral diarrhea virus, vesicular stomatitis virus, and BHV-2, antisera to PRV and equine herpesvirus-1, and normal sera from lamb, chick, and mouse were negative in this test, 10 Previous results from testing a large number of serum samples from several herds have also shown that the anti-gIII ELISA is more sensitive than standard SN tests, mainly in detecting positive samples with low antibody titers. 10 These findings support the use of this test for screening purposes, because it is also simple, fast, and easy to perform. The degree of clinical protection after challenge did During the standardization of the test, the requirenot correlate with the serum neutralizing antibody re-ment of adsorbing the coated plates with gIII-negative sponse induced by vaccination. Although the SN titers vaccinated serum prior to incubation with test samples developed 30 days after vaccination by most of the became clear. In contrast with some PRV differential animals were low (< 1:2, 1:2, and 1:4), these animals kits, which use genetically purified marker antigen to were satisfactorily protected from challenge. These and coat the wells, this test used semipurified BHV-1 anprevious results 2 support the generally accepted view tigens. Consequently, during incubation with test sera, that the humoral antibodies represent only part of the a broad spectrum of antibody-antigen complex forimmune response to BHV-1. mation might take place, possibly leading to a steric One of the major shortcomings among BHV-1 vac-hindrance that can affect the accessibility of gIII to its specific MAbs. This problem will certainly be reduced in the future by the use of a purified antigen to coat the plates.
The dynamic of the IgM response developed by the controls after the challenge is typical of a primary infection with BHV-1 as previously characterized. 3, 19 Most of the vaccinates did not show a significant increase in IgM titers after challenge. Previous studies are somewhat controversial about the IgM response during subsequent exposures to BHV-1. Whereas BHVl-induced abortion in latently infected cows and reactivation of latent infection by corticosteroid administration induce a secondary IgM response, reexposure intranasally did not result in an increase in anti-IgM levels. 3, 19 Our results support the observations that the gIII glycoprotein does represent an appropriate choice for a "marker" deletion in BHV-1 because it is one of the most abundant and immunogenic antigens of BHV-1 and its deletion does not preclude the immunogenicity of the virus. The use of this strain in conjunction with a specific anti-gIII blocking ELISA permits the distinction between vaccinated and infected animals and will be a significant contribution to the current efforts to control the BHV-1 infection in several countries. An effective and suitable "marker" vaccine is also important for the use of BHV-1 vaccines as vectors for other antigens.
